Tags

Type your tag names separated by a space and hit enter

Biochemical and therapeutic effects of Omega-3 fatty acids in sickle cell disease.
Complement Ther Med. 2020 Aug; 52:102482.CT

Abstract

Sickle cell disease (SCD) is a hematologic disorder with complex pathophysiology that includes chronic hemolysis, vaso-occlusion and inflammation. Increased leukocyte-erythrocyte-endothelial interactions, due to upregulated expression of adhesion molecules and activated endothelium, are thought to play a primary role in initiation and progression of SCD vaso-occlusive crisis and end-organ damage. Several new pathophysiology-based therapeutic options for SCD are being developed, chiefly targeting the inflammatory pathways. Omega-3 fatty acids are polyunsaturated fatty acids that are known to have effects on diverse physiological processes. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are the principal biologically active omega-3 fatty acids. The therapeutic effects of DHA and EPA on chronic inflammatory disorders and cardiovascular diseases are well recognized. The therapeutic effects of omega-3 fatty acids are attributed to their anti-inflammatory and anti-thrombotic eicosanoids, and the novel class of EPA and DHA derived lipid mediators: resolvins, protectins and maresins. Blood cell membranes of patients with SCD have abnormal fatty acids composition characterized by high ratio of pro-inflammatory arachidonic acid (AA) to anti-inflammatory DHA and EPA (high omega-6/omega-3 ratio). In addition, experimental and clinical studies provide evidence that treatment with DHA does confer improvement in rheological properties of sickle RBC, inflammation and hemolysis. The clinical studies have shown improvements in VOC rate, markers of inflammation, adhesion, and hemolysis. In toto, the results of studies on the therapeutic effects of omega-3 fatty acids in SCD provide good body of evidence that omega-3 fatty acids could be a safe and effective treatment for SCD.

Authors+Show Affiliations

Sanofi Genzyme, Cambridge, MA, United States; Center for Molecular Biology and Biotechnology (CMBB), Florida Atlantic University (FAU), FL, United States.Center for Molecular Biology and Biotechnology (CMBB), Florida Atlantic University (FAU), FL, United States; Alpha Cognition, Inc. West Palm Beach, FL, United States.Dana-Farber / Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, United States. Electronic address: Matthew.Heeney@childrens.harvard.edu.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32951732

Citation

Daak, Ahmed A., et al. "Biochemical and Therapeutic Effects of Omega-3 Fatty Acids in Sickle Cell Disease." Complementary Therapies in Medicine, vol. 52, 2020, p. 102482.
Daak AA, Lopez-Toledano MA, Heeney MM. Biochemical and therapeutic effects of Omega-3 fatty acids in sickle cell disease. Complement Ther Med. 2020;52:102482.
Daak, A. A., Lopez-Toledano, M. A., & Heeney, M. M. (2020). Biochemical and therapeutic effects of Omega-3 fatty acids in sickle cell disease. Complementary Therapies in Medicine, 52, 102482. https://doi.org/10.1016/j.ctim.2020.102482
Daak AA, Lopez-Toledano MA, Heeney MM. Biochemical and Therapeutic Effects of Omega-3 Fatty Acids in Sickle Cell Disease. Complement Ther Med. 2020;52:102482. PubMed PMID: 32951732.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Biochemical and therapeutic effects of Omega-3 fatty acids in sickle cell disease. AU - Daak,Ahmed A, AU - Lopez-Toledano,Miguel A, AU - Heeney,Matthew M, Y1 - 2020/06/09/ PY - 2020/02/11/received PY - 2020/06/02/revised PY - 2020/06/08/accepted PY - 2020/9/21/entrez PY - 2020/9/22/pubmed PY - 2021/5/19/medline KW - Anti-inflammatory KW - Inflammation KW - Omega-3 fatty acids KW - Sickle cell disease SP - 102482 EP - 102482 JF - Complementary therapies in medicine JO - Complement Ther Med VL - 52 N2 - Sickle cell disease (SCD) is a hematologic disorder with complex pathophysiology that includes chronic hemolysis, vaso-occlusion and inflammation. Increased leukocyte-erythrocyte-endothelial interactions, due to upregulated expression of adhesion molecules and activated endothelium, are thought to play a primary role in initiation and progression of SCD vaso-occlusive crisis and end-organ damage. Several new pathophysiology-based therapeutic options for SCD are being developed, chiefly targeting the inflammatory pathways. Omega-3 fatty acids are polyunsaturated fatty acids that are known to have effects on diverse physiological processes. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are the principal biologically active omega-3 fatty acids. The therapeutic effects of DHA and EPA on chronic inflammatory disorders and cardiovascular diseases are well recognized. The therapeutic effects of omega-3 fatty acids are attributed to their anti-inflammatory and anti-thrombotic eicosanoids, and the novel class of EPA and DHA derived lipid mediators: resolvins, protectins and maresins. Blood cell membranes of patients with SCD have abnormal fatty acids composition characterized by high ratio of pro-inflammatory arachidonic acid (AA) to anti-inflammatory DHA and EPA (high omega-6/omega-3 ratio). In addition, experimental and clinical studies provide evidence that treatment with DHA does confer improvement in rheological properties of sickle RBC, inflammation and hemolysis. The clinical studies have shown improvements in VOC rate, markers of inflammation, adhesion, and hemolysis. In toto, the results of studies on the therapeutic effects of omega-3 fatty acids in SCD provide good body of evidence that omega-3 fatty acids could be a safe and effective treatment for SCD. SN - 1873-6963 UR - https://www.unboundmedicine.com/medline/citation/32951732/Biochemical_and_therapeutic_effects_of_Omega_3_fatty_acids_in_sickle_cell_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0965-2299(20)30287-9 DB - PRIME DP - Unbound Medicine ER -